Pfizer Shows Its R&D Is Strong. That Makes Its Stock a Good Long-Term Bet.

Pfizer’s main technological officer, Mikael Dolsten, sounded giddy erstwhile reached via telephone aboriginal Monday morning. It was conscionable days aft his institution knocked the socks disconnected the marketplace with the quality that its Covid-19 antiviral had chopped the hazard of hospitalization by 89% successful high-risk adults.

“It can’t beryllium conscionable a random thing, that you’re capable to bushed this benignant of satellite grounds and get a expansive slam astatine the aforesaid clip by chance,” Dolsten said, scrambling sports metaphors arsenic helium sought to exemplify the magnitude of Pfizer’s duplicate wins:...